Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study
ABSTRACT Background Although neoadjuvant chemoimmunotherapy has emerged as a promising approach for resectable non‐small cell lung cancer (NSCLC), comparative real‐world data on different PD‐1 inhibitors are limited. This study compared the clinical efficacy, pathological response, survival, and saf...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318850192998400 |
|---|---|
| author | Bo Yan Xiaoxuan Sun Yan Sheng Ran Zhang Yanjun Su Yulong Chen |
| author_facet | Bo Yan Xiaoxuan Sun Yan Sheng Ran Zhang Yanjun Su Yulong Chen |
| author_sort | Bo Yan |
| collection | DOAJ |
| description | ABSTRACT Background Although neoadjuvant chemoimmunotherapy has emerged as a promising approach for resectable non‐small cell lung cancer (NSCLC), comparative real‐world data on different PD‐1 inhibitors are limited. This study compared the clinical efficacy, pathological response, survival, and safety of four PD‐1 inhibitors—pembrolizumab, tislelizumab, camrelizumab, and sintilimab—in patients with Stage II–IIIa NSCLC. Methods We retrospectively reviewed 199 patients with resectable Stage II–IIIa NSCLC treated with neoadjuvant PD‐1 inhibitors plus platinum‐based chemotherapy from January 2018 to December 2024. After excluding 50 non‐surgical cases, 149 patients were included. Outcomes compared included pathological response (pathological complete response, pCR; major pathological response, MPR), recurrence, disease‐free survival (DFS), overall survival (OS), and adverse events. Results pCR and MPR rates were 52.2% and 58.0% (pembrolizumab), 67.6% and 75.7% (tislelizumab), 71.4% and 71.4% (camrelizumab), and 47.2% and 61.1% (sintilimab), respectively. Differences in pCR/MPR were not statistically significant. However, OS differed significantly across groups (p < 0.05), favoring pembrolizumab and tislelizumab. No significant differences were observed in progression‐free survival (PFS) or recurrence among patients with pCR. Grade ≥ 3 treatment‐related adverse events occurred in 27.0%–42.9% of patients, lowest in the tislelizumab group. Conclusion All treatment regimens elicited substantial pathological responses and exhibited acceptable safety profiles. Pembrolizumab and tislelizumab were associated with better OS and lower toxicity, supporting their preferential use in neoadjuvant therapy for resectable NSCLC. |
| format | Article |
| id | doaj-art-3cec4de8f4df4792b74a5995b8d9d536 |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-3cec4de8f4df4792b74a5995b8d9d5362025-08-20T03:50:43ZengWileyThoracic Cancer1759-77061759-77142025-07-011613n/an/a10.1111/1759-7714.70123Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective StudyBo Yan0Xiaoxuan Sun1Yan Sheng2Ran Zhang3Yanjun Su4Yulong Chen5Department of Radiotherapy National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Cancer Tianjin Cancer Hospital Airport Hospital National Clinical Research Center for Cancer Tianjin ChinaDepartment of Pathology Tianjin Cancer Hospital Airport Hospital National Clinical Research Center for Cancer Tianjin ChinaDepartment of Thoracic Cancer Tianjin Cancer Hospital Airport Hospital National Clinical Research Center for Cancer Tianjin ChinaDepartment of Lung Cancer Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin ChinaDepartment of Lung Cancer Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin ChinaABSTRACT Background Although neoadjuvant chemoimmunotherapy has emerged as a promising approach for resectable non‐small cell lung cancer (NSCLC), comparative real‐world data on different PD‐1 inhibitors are limited. This study compared the clinical efficacy, pathological response, survival, and safety of four PD‐1 inhibitors—pembrolizumab, tislelizumab, camrelizumab, and sintilimab—in patients with Stage II–IIIa NSCLC. Methods We retrospectively reviewed 199 patients with resectable Stage II–IIIa NSCLC treated with neoadjuvant PD‐1 inhibitors plus platinum‐based chemotherapy from January 2018 to December 2024. After excluding 50 non‐surgical cases, 149 patients were included. Outcomes compared included pathological response (pathological complete response, pCR; major pathological response, MPR), recurrence, disease‐free survival (DFS), overall survival (OS), and adverse events. Results pCR and MPR rates were 52.2% and 58.0% (pembrolizumab), 67.6% and 75.7% (tislelizumab), 71.4% and 71.4% (camrelizumab), and 47.2% and 61.1% (sintilimab), respectively. Differences in pCR/MPR were not statistically significant. However, OS differed significantly across groups (p < 0.05), favoring pembrolizumab and tislelizumab. No significant differences were observed in progression‐free survival (PFS) or recurrence among patients with pCR. Grade ≥ 3 treatment‐related adverse events occurred in 27.0%–42.9% of patients, lowest in the tislelizumab group. Conclusion All treatment regimens elicited substantial pathological responses and exhibited acceptable safety profiles. Pembrolizumab and tislelizumab were associated with better OS and lower toxicity, supporting their preferential use in neoadjuvant therapy for resectable NSCLC.https://doi.org/10.1111/1759-7714.70123chemoimmunotherapyimmune checkpoint inhibitorsneoadjuvant therapynon‐small cell lung cancersurgery |
| spellingShingle | Bo Yan Xiaoxuan Sun Yan Sheng Ran Zhang Yanjun Su Yulong Chen Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study Thoracic Cancer chemoimmunotherapy immune checkpoint inhibitors neoadjuvant therapy non‐small cell lung cancer surgery |
| title | Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study |
| title_full | Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study |
| title_fullStr | Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study |
| title_full_unstemmed | Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study |
| title_short | Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study |
| title_sort | comparative efficacy of pd 1 inhibitor based neoadjuvant chemoimmunotherapy regimens for resectable stage ii iiia nsclc a real world retrospective study |
| topic | chemoimmunotherapy immune checkpoint inhibitors neoadjuvant therapy non‐small cell lung cancer surgery |
| url | https://doi.org/10.1111/1759-7714.70123 |
| work_keys_str_mv | AT boyan comparativeefficacyofpd1inhibitorbasedneoadjuvantchemoimmunotherapyregimensforresectablestageiiiiiansclcarealworldretrospectivestudy AT xiaoxuansun comparativeefficacyofpd1inhibitorbasedneoadjuvantchemoimmunotherapyregimensforresectablestageiiiiiansclcarealworldretrospectivestudy AT yansheng comparativeefficacyofpd1inhibitorbasedneoadjuvantchemoimmunotherapyregimensforresectablestageiiiiiansclcarealworldretrospectivestudy AT ranzhang comparativeefficacyofpd1inhibitorbasedneoadjuvantchemoimmunotherapyregimensforresectablestageiiiiiansclcarealworldretrospectivestudy AT yanjunsu comparativeefficacyofpd1inhibitorbasedneoadjuvantchemoimmunotherapyregimensforresectablestageiiiiiansclcarealworldretrospectivestudy AT yulongchen comparativeefficacyofpd1inhibitorbasedneoadjuvantchemoimmunotherapyregimensforresectablestageiiiiiansclcarealworldretrospectivestudy |